Medical Device Development Pathways in the U.S. and EU

This white paper outlines the development processes, regulatory landscape, and approval pathways for medical devices in the United States and the European Union. It highlights the key differences between medical devices and drugs, emphasizing that while both follow similar development steps, they are subject to distinct regulatory requirements and clinical investigation rules. The paper details how the classification of medical devices based on their risk to patients influences the regulatory scrutiny they face. It also discusses recent updates in U.S. regulations, including the 21st Century Cures Act, which introduces provisions affecting medical device sponsors, such as expedited review programs and new regulatory pathways for rare diseases. In the EU, the paper covers the transition from previous directives to the new Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), which aim to enhance safety standards and uniformity across member states. The document serves as a comprehensive guide for sponsors seeking to navigate the complexities of medical device development and approval.